oral semaglutide nejm New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis GLP1s cut appetite, but muscle recovery Color:Orange

oral semaglutide nejm New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis GLP1s cut appetite, but muscle recovery Color:Orange

GLP1s cut appetite, but the add-ons decide how much extra fat you actually lose. Cagrilintide pushes weight loss harder with semaglutide and tirzepatide, not with retatrutide. NAD, 5-Amino-1MQ, and MOTS-c all boost

CagriSema 2.4 mg/2.4 mg also led to consistent reductions in BP across a wide range of participant subgroups, including individuals with resistant hypertension who are often unresponsive to BP-lowering treatments

muscle recovery

Color:Orange

doi: 10.1016/j.parkreldis.2016.08.019